This archived news article is over 5 years old.

Modified Crispr Technique Shows Great Promise For Gene Therapy Applications

Joanna Lawrence
13th August, 2016

The revolutionary genome-editing technology CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats associated nuclease 9) continues to break new ground in medical research, particularly in the promising field of gene therapy. Known for its simplicity and versatility, CRISPR-Cas9 is now making strides in the development of treatments for genetic diseases through in vivo applications in adult rodent models, signaling a potential leap towards human clinical use. Historically, CRISPR-Cas9's journey in therapeutic applications was confined to in vitro studies or animal germlines, with limitations stemming from ethical considerations and technical challenges. However, recent advancements have showcased its efficacy in correcting gene mutations directly within living organisms, marking a significant step towards its application in treating human diseases. CRISPR-Cas9 operates by utilizing a guide RNA to direct the Cas9 enzyme to specific DNA sequences, where it makes precise cuts. This process allows for the targeted editing of genes, either by disrupting gene function or by facilitating the correction of genetic mutations through the cell's repair mechanisms. This method holds a clear advantage over older gene-editing technologies due to its efficiency, ease of design, and ability to target multiple genes simultaneously. The recent breakthroughs involve using CRISPR-Cas9 for in vivo gene therapy, successfully treating mouse models of human genetic disorders such as Duchenne muscular dystrophy and hereditary liver diseases. These studies, delivered through methods like intramuscular and intravenous injections, utilized adeno-associated viruses (AAVs) as vectors for delivering the CRISPR-Cas9 components, demonstrating a viable pathway for human application. Despite these exciting advancements, significant hurdles remain before CRISPR-Cas9 can be broadly applied in clinical settings. Key challenges include minimizing off-target effects, which can lead to unintended genetic modifications; enhancing the efficiency of homology-directed repair, crucial for precise gene correction; ensuring the fitness and viability of edited cells; addressing the immunogenicity of CRISPR components and delivery vectors; and refining in vivo delivery methods for efficiency, specificity, and translatability to humans. Efforts to overcome these obstacles are ongoing, with strategies focusing on improving the design of guide RNAs, optimizing CRISPR-Cas9 delivery methods, and developing less immunogenic delivery vehicles. Moreover, the diversity in genetic mutations across individuals necessitates personalized approaches to therapy, complicating the scalability and commercialization of CRISPR-based treatments. In summary, while recent successes in using CRISPR-Cas9 for in vivo gene therapy in animal models have illuminated the path towards treating genetic diseases in humans, the journey from bench to bedside is fraught with technical and ethical challenges. Continued research and innovation are critical to address these issues, with the hope that CRISPR-Cas9 will eventually revolutionize the treatment of genetic disorders, offering new hope to patients worldwide. The promise of CRISPR-Cas9 in gene therapy shines bright, but the path forward requires a concerted effort to ensure its safe, effective, and equitable use in clinical settings. REFERENCE Dai, W.-J., et al. CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Molecular Therapy - Nucleic Acids, 5, e349. August 2016.